Table 1.

List of clinical trials investigating drugs/inhibitors dedicated to DNA repair abnormalities in breast cancer

Serial No.	Title of clinical trial	Drugs/inhibitors	Intervention	Reference
1	PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer	Olaparib and Tremelimumab	To cripple DNA double-strand break repair ability via PARP inhibitors in solid tumors such as ovarian cancer; the clinical trial of the PARP enzyme.	73
2.	Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer.	LY2606368	A Chk1/2 inhibitor in several solid tumors, including breast tumors having BRCA1/2 defects.	74
3.	ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer	ABT-888 and temozolomide	To test PARP inhibitor ABT-188 to enhance the potential of chemotherapeutic agents such as temozolomide to induce cell death.	75
4.	Veliparib and Atezolizumab Either Alone or in Combination in Treating Patients With Stage III–IV Triple Negative Breast Cancer	Atezolizumab Other: Laboratory Biomarker Analysis Drug: Veliparib	A phase II multiple-arm, open-label, randomized study of PARP inhibition (Veliparib; ABT-888) and anti-PD-L1 therapy (Atezolizumab; MPDL3280A) either alone or in combination in homologous DNA repair deficient triple negative breast cancer	76